{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T08:27:28Z","timestamp":1786696048953,"version":"build-2736575974"},"reference-count":44,"publisher":"AOSIS","issue":"1","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Background:\u00a0Cystic fibrosis transmembrane conductance regulator modulator (CFTRm) therapy has transformed cystic fibrosis (CF) outcomes in high-income settings, yet access remains severely limited in South Africa. Patient-reported outcomes of CFTRm are underexplored.\nObjectives:\u00a0To describe the lived experiences of South African people living with cystic fibrosis (PLwCF) following CFTRm initiation, focusing on respiratory symptoms, treatment burden, physical activity, social and recreational participation, and well-being.\nMethod:\u00a0A convergent mixed-methods design incorporated an online survey (n\u00a0= 37; 48% response rate) and semi-structured interviews (n\u00a0= 6) with PLwCF aged &gt; 6 years. Chi-square and Fisher\u2019s exact tests compared pre- and post-CFTRm responses; qualitative data underwent inductive thematic analysis.\nResults:\u00a0Participants reported dramatic improvements from pre- to post-CFTRm: daily distressing respiratory symptoms decreased from 73% to 6% (p\u00a0&lt; 0.0001); perceived therapy burden shifted from predominantly high (78%) to predominantly low burden (87%), with a similar decline in duration of respiratory treatment: before CFTRm, 63% of participants spent &gt; 1 h per day on respiratory treatment compared to 14% after CFTRm (p\u00a0&lt; 0.0001); regular exercise increased from 62% to 92% (p\u00a0= 0.04); frequent social participation from 22% to 49% (p\u00a0= 0.006); and perceived excellent health increased from 5% to 65% (p\u00a0&lt; 0.0001). Ten qualitative themes emerged: (1) respiratory health transformation, (2) reduced treatment burden, (3) normalisation of daily life, (4) enhanced physical capacity and participation, (5) profound psychosocial and (6) family impact, (7) improved nutrition, (8) reduced hospitalisations, (9) improved energy, and (10) altruistic hope for universal access.\nConclusion:\u00a0Cystic fibrosis transmembrane conductance regulator modulator profoundly transforms the lived experiences of South African PLwCF providing compelling evidence to advocate for equitable access in resource-limited settings.\nClinical Implications:\u00a0National funding and rollout of CFTRm for all eligible PLwCF in South Africa are urgently needed, together with interdisciplinary support to navigate modifications to existing care regimens.<\/jats:p>","DOI":"10.4102\/sajp.v82i1.2422","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:33:40Z","timestamp":1786692820000},"update-policy":"https:\/\/doi.org\/10.4102\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cystic fibrosis transmembrane conductance regulator modulator therapy and lived experiences in South Africa: A mixed-methods study"],"prefix":"10.4102","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5193-918X","authenticated-orcid":false,"given":"Brenda M.","family":"Morrow","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1148-4747","authenticated-orcid":false,"given":"Janine","family":"Verstraete","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3375-5470","authenticated-orcid":false,"given":"Sinead","family":"Thistlewhite","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6322-5207","authenticated-orcid":false,"given":"Carese","family":"Abrahams","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3716-4234","authenticated-orcid":false,"given":"Teboho N.","family":"Nkosi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8514-5952","authenticated-orcid":false,"given":"Tyra","family":"Donnelly","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1938-7038","authenticated-orcid":false,"given":"Dalziel","family":"Kennedy","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-6137","authenticated-orcid":false,"given":"Marco","family":"Zampoli","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03p74gp79","id-type":"ROR","asserted-by":"publisher"}],"name":"University of Cape Town"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2580","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"Ancel, J., Launois, C., Perotin, J.M., Ravoninjatovo, B., Mulette, P., Hagenburg, J. et al., 2022, \u2018Health-related quality of life in adults with cystic fibrosis: Familial, occupational, social, and mental health predictors\u2019, Healthcare (Basel) 10(7), 1351. https:\/\/doi.org\/10.3390\/healthcare10071351","DOI":"10.3390\/healthcare10071351"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bacalhau, M., Camargo, M., Magalhaes-Ghiotto, G.A.V., Drumond, S., Castelletti, C.H.M. & Lopes-Pacheco, M., 2023, \u2018Elexacaftor-tezacaftor-ivacaftor: A life-changing triple combination of CFTR modulator drugs for cystic fibrosis\u2019, Pharmaceuticals (Basel) 16(3), 410. https:\/\/doi.org\/10.3390\/ph16030410","DOI":"10.3390\/ph16030410"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Bagci, R., Vardar-Yagli, N., Saglam, M., Calik Kutukcu, E., Inal-Ince, D., Sener, F. et al., 2023, \u2018Body functions and structure, activity, and participation limitations of adult cystic fibrosis patients under the international classification of functioning, disability, and health framework\u2019, Physiotherapy Theory and Practice 39(7), 1417\u20131427. https:\/\/doi.org\/10.1080\/09593985.2022.2041780","DOI":"10.1080\/09593985.2022.2041780"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Basile, M., Polo, J., Henthorne, K., DeCelie-Germana, J., Galvin, S. & Wang, J., 2024, \u2018The impact of elexacaftor\/tezacaftor\/ivacaftor on cystic fibrosis health-related quality of life and decision-making about daily treatment regimens: A mixed methods exploratory study\u2019, Therapeutic Advances in Chronic Disease 15, 20406223241264477. https:\/\/doi.org\/10.1177\/20406223241264477","DOI":"10.1177\/20406223241264477"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Berthold, A., Barr, E., Kasi, A., Lichten, L. & Hunt, W.R., 2024, \u2018Perception and participation in sport and exercise in cystic fibrosis: The impact of CFTR modulators\u2019, Respiratory Medicine 235, 107840. https:\/\/doi.org\/10.1016\/j.rmed.2024.107840","DOI":"10.1016\/j.rmed.2024.107840"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C. et al., 2018, \u2018Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor\u2019, Thorax 73(8), 731\u2013740. https:\/\/doi.org\/10.1136\/thoraxjnl-2017-210394","DOI":"10.1136\/thoraxjnl-2017-210394"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Braun, V. & Clarke, V., 2006, \u2018Using thematic analysis in psychology\u2019, Qualitative Research in Psychology 3(2), 77\u2013101. https:\/\/doi.org\/10.1191\/1478088706qp063oa","DOI":"10.1191\/1478088706qp063oa"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Buniotto, F., Tridello, G., De Scolari, A., Meneghelli, I., Pintani, E., Perobelli, S, et al., 2025, \u2018Improved quality of life in cystic fibrosis patients observed up to 36 months after starting elexacaftor\/tezacaftor\/ivacaftor treatment\u2019, Journal of Patient-Reported Outcomes 9(1), 48. https:\/\/doi.org\/10.1186\/s41687-025-00879-0","DOI":"10.1186\/s41687-025-00879-0"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Castellani, C. & Assael, B.M., 2017, \u2018Cystic fibrosis: A clinical view\u2019, Cellular and Molecular Life Sciences 74(1), 129\u2013140. https:\/\/doi.org\/10.1007\/s00018-016-2393-9","DOI":"10.1007\/s00018-016-2393-9"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Dellon, E.P. & Prieur, M.G., 2025, \u2018After the honeymoon: Real world experiences with CFTR modulators\u2019, Journal of Cystic Fibrosis 24(4), 637\u2013638. https:\/\/doi.org\/10.1016\/j.jcf.2025.07.006","DOI":"10.1016\/j.jcf.2025.07.006"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Dobra, R., Carroll, S., Davies, J.C., Dowdall, F., Duff, A., Elderton, A. et al., 2025, \u2018Exploring the complexity of cystic fibrosis (CF) and psychosocial wellbeing in the 2020s: Current and future challenges\u2019, Paediatric Respiratory Reviews 54, 35\u201342. https:\/\/doi.org\/10.1016\/j.prrv.2024.08.001","DOI":"10.1016\/j.prrv.2024.08.001"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Dziuban, E.J., Saab-Abazeed, L., Chaudhry, S.R., Streetman, D.S. & Nasr, S.Z., 2010, \u2018Identifying barriers to treatment adherence and related attitudinal patterns in adolescents with cystic fibrosis\u2019, Pediatric Pulmonology 45(5), 450\u2013458. https:\/\/doi.org\/10.1002\/ppul.21195","DOI":"10.1002\/ppul.21195"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Edwards, S.J., Farrar, B.G., Ennis, K., Downes, N., Wakefield, V., Mackenzie, I. et al., 2025, \u2018Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: A systematic review and economic evaluation\u2019, Health Technology Assessment 29(19), 1\u2013111. https:\/\/doi.org\/10.3310\/CPLD8546","DOI":"10.3310\/CPLD8546"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Elborn, J.S., 2016, \u2018Cystic fibrosis\u2019, The Lancet 388(10059), 2519\u20132531. https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","DOI":"10.1016\/S0140-6736(16)00576-6"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Felipe Montiel, A., Fernandez, A.A., Amigo, M.C., Traversi, L., Clofent Alarc\u00f3n, D., Reyes, K.L. et al., 2024, \u2018The ageing of people living with cystic fibrosis: What to expect now?\u2019, European Respiratory Review 33(174), 240071. https:\/\/doi.org\/10.1183\/16000617.0071-2024","DOI":"10.1183\/16000617.0071-2024"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Gifford, A.H., Mayer-Hamblett, N., Pearson, K. & Nichols, D.P., 2020, \u2018Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy\u2019, Journal of Cystic Fibrosis 19(5), 762\u2013767. https:\/\/doi.org\/10.1016\/j.jcf.2019.11.007","DOI":"10.1016\/j.jcf.2019.11.007"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Gomes, D.C., Longo, E., De Camargo, O.K., De Sousa Dantas, D., Ferreira, H.N., Regalado, I.C. et al., 2019, \u2018Common content between quality of life questionnaires for children with cystic fibrosis and the international classification of functionality, disability and health\u2019, Journal of Rehabilitation Medicine 51(8), 582\u2013586. https:\/\/doi.org\/10.2340\/16501977-2571","DOI":"10.2340\/16501977-2571"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Graeber, S.Y., Vitzthum, C., Pallenberg, S.T., Naehrlich, L., Stahl, M., Rohrbach, A. et al., 2022, \u2018Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on CFTR function in patients with cystic fibrosis and one or two F508del alleles\u2019, American Journal of Respiratory and Critical Care Medicine 205(5), 540\u2013549. https:\/\/doi.org\/10.1164\/rccm.202110-2249OC","DOI":"10.1164\/rccm.202110-2249OC"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Griese, M., Costa, S., Linnemann, R.W., Mall, M.A., McKone, E.F., Polineni, D. et al., 2021, \u2018Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor for 24 weeks or longer in people with cystic fibrosis and one or more F508del alleles: Interim results of an open-label phase 3 clinical trial\u2019, American Journal of Respiratory and Critical Care Medicine 203(3), 381\u2013385. https:\/\/doi.org\/10.1164\/rccm.202008-3176LE","DOI":"10.1164\/rccm.202008-3176LE"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Gruber, W., Welsner, M., Blosch, C., Dillenhoefer, S., Olivier, M., Brinkmann, F. et al., 2023, \u2018Long-term follow-up of health-related quality of life and short-term intervention with CFTR modulator therapy in adults with cystic fibrosis\u2019, Healthcare (Basel) 11(21), 2873. https:\/\/doi.org\/10.3390\/healthcare11212873","DOI":"10.3390\/healthcare11212873"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Heijerman, H.G.M., McKone, E.F., Downey, D.G., Van Braeckel, E., Rowe, S.M., Tullis, E. et al., 2019, \u2018Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial\u2019, The Lancet 394(10212), 1940\u20131948. https:\/\/doi.org\/10.1016\/S0140-6736(19)32597-8","DOI":"10.1016\/S0140-6736(19)32597-8"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Hisert, K.B., Birket, S.E., Clancy, J.P., Downey, D.G., Engelhardt, J.F., Fajac, I. et al., 2023, \u2018Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy\u2019, Lancet Respiratory Medicine 11(10), 916\u2013931. https:\/\/doi.org\/10.1016\/S2213-2600(23)00324-7","DOI":"10.1016\/S2213-2600(23)00324-7"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"King, J.A., Nichols, A.L., Bentley, S., Carr, S.B. & Davies, J.C., 2022, \u2018An update on CFTR modulators as new therapies for cystic fibrosis\u2019, Paediatric Drugs 24(4), 321\u2013333. https:\/\/doi.org\/10.1007\/s40272-022-00509-y","DOI":"10.1007\/s40272-022-00509-y"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Malterud, K., Siersma, V.D. & Guassora, A.D., 2016, \u2018Sample size in qualitative interview studies: Guided by information power\u2019, Qualitative Health Research 26(13), 1753\u20131760. https:\/\/doi.org\/10.1177\/1049732315617444","DOI":"10.1177\/1049732315617444"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Mandrusiak, A., MacDonald, J. & Watter, P., 2009, \u2018The International Classification of Functioning, Disability and Health: An effective model for describing young people with cystic fibrosis\u2019, Child: Care, Health and Development 35(1), 2\u20134. https:\/\/doi.org\/10.1111\/j.1365-2214.2008.00903.x","DOI":"10.1111\/j.1365-2214.2008.00903.x"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Marshall, L.Z., Espinosa, R., Starner, C.I. & Gleason, P.P., 2023, \u2018Real-world outcomes and direct care cost before and after elexacaftor\/tezacaftor\/ivacaftor initiation in commercially insured members with cystic fibrosis\u2019, Journal of Managed Care and Specialty Pharmacy 29(6), 599\u2013606. https:\/\/doi.org\/10.18553\/jmcp.2023.29.6.599","DOI":"10.18553\/jmcp.2023.29.6.599"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Mayer-Hamblett, N., Ratjen, F., Russell, R., Donaldson, S.H., Riekert, K.A., Sawicki, G.S. et al., 2023, \u2018Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): Results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials\u2019, Lancet Respiratory Medicine 11(4), 329\u2013340. https:\/\/doi.org\/10.1016\/S2213-2600(22)00434-9","DOI":"10.1016\/S2213-2600(22)00434-9"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Middleton, P.G., Mall, M.A., Drevinek, P., Lands, L.C., McKone, E.F., Polineni, D. et al., 2019, \u2018Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele\u2019, New England Journal of Medicine 381(19), 1809\u20131819. https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1056\/NEJMoa1908639"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Padoa, C., Goldman, A., Jenkins, T. & Ramsay, M., 1999, \u2018Cystic fibrosis carrier frequencies in populations of African origin\u2019, Journal of Medical Genetics 36(1), 41\u201344. https:\/\/doi.org\/10.1136\/jmg.36.1.41","DOI":"10.1136\/jmg.36.1.41"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Page, A., Goldenberg, A. & Matthews, A.L., 2022, \u2018Lived experiences of individuals with cystic fibrosis on CFTR-modulators\u2019, BMC Pulmonary Medicine 22(1), 42. https:\/\/doi.org\/10.1186\/s12890-022-01825-2","DOI":"10.1186\/s12890-022-01825-2"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Quittner, A.L., Goldbeck, L., Abbott, J., Duff, A., Lambrecht, P., Sol\u00e9, A. et al., 2014, \u2018Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: Results of the International Depression Epidemiological Study across nine countries\u2019, Thorax 69(12), 1090\u20131097. https:\/\/doi.org\/10.1136\/thoraxjnl-2014-205983","DOI":"10.1136\/thoraxjnl-2014-205983"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Sawicki, G.S., Sellers, D.E. & Robinson, W.M., 2009, \u2018High treatment burden in adults with cystic fibrosis: Challenges to disease self-management\u2019, Journal of Cystic Fibrosis 8(2), 91\u201396. https:\/\/doi.org\/10.1016\/j.jcf.2008.09.007","DOI":"10.1016\/j.jcf.2008.09.007"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sharma, D., Xing, S., Hung, Y.T., Caskey, R.N., Dowell, M.L. & Touchette, D.R., 2018, \u2018Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States\u2019, Orphanet Journal of Rare Diseases 13(1), 172. https:\/\/doi.org\/10.1186\/s13023-018-0914-3","DOI":"10.1186\/s13023-018-0914-3"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Smith, A. & Barry, M., 2020, \u2018Utilisation, expenditure and cost-effectiveness of cystic fibrosis drugs in Ireland: A retrospective analysis of a national pharmacy claims database\u2019, BMJ Open 10(11), e040806. https:\/\/doi.org\/10.1136\/bmjopen-2020-040806","DOI":"10.1136\/bmjopen-2020-040806"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Terlizzi, V. & Lopes-Pacheco, M., 2025, \u2018Cystic fibrosis: New challenges and perspectives beyond elexacaftor\/tezacaftor\/ivacaftor\u2019, Therapeutic Advances in Respiratory Disease 19, 17534666251323194. https:\/\/doi.org\/10.1177\/17534666251323194","DOI":"10.1177\/17534666251323194"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Vadagam, P., Kamal, K.M., Covvey, J.R., Giannetti, V. & Mukherjee, K., 2018, \u2018Cost-effectiveness and budget impact of lumacaftor\/ivacaftor in the treatment of cystic fibrosis\u2019, Journal of Managed Care and Specialty Pharmacy 24(10), 987\u2013997. https:\/\/doi.org\/10.18553\/jmcp.2018.24.10.987","DOI":"10.18553\/jmcp.2018.24.10.987"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Van Citters, A.D., Aliaj, E., Alvarez, J.A., Brown, C.D., Cary, J., Cravens, R. et al., 2025, \u2018Wellness in the modulator era: An observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis\u2019, Journal of Cystic Fibrosis 24(4), 642\u2013651. https:\/\/doi.org\/10.1016\/j.jcf.2024.06.010","DOI":"10.1016\/j.jcf.2024.06.010"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Wherry, K., Williamson, I., Chapman, R.H. & Kuntz, K.M., 2020, \u2018Cost-effectiveness of ivacaftor therapy for treatment of cystic fibrosis patients with the G551D gating mutation\u2019, Value in Health 23(10), 1332\u20131339. https:\/\/doi.org\/10.1016\/j.jval.2020.05.016","DOI":"10.1016\/j.jval.2020.05.016"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Whiting, P., Al, M., Burgers, L., Westwood, M., Ryder, S., Hoogendoorn, M. et al., 2014, \u2018Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: A systematic review and cost-effectiveness analysis\u2019, Health Technology Assessment 18(18), 1\u2013106. https:\/\/doi.org\/10.3310\/hta18180","DOI":"10.3310\/hta18180"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Zampoli, M., Baird, C., Morrow, B., Verstraete, J., Calligaro, G. & Seale, M., 2025a, \u2018Cystic fibrosis care in South Africa: Facing the challenge of diversity and inequality\u2019, Pediatric Pulmonology 60(10), e71338. https:\/\/doi.org\/10.1002\/ppul.71338","DOI":"10.1002\/ppul.71338"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Zampoli, M., Morrow, B.M. & Paul, G., 2023a, \u2018Real-world disparities and ethical considerations with access to CFTR modulator drugs: Mind the gap!\u2019, Frontiers in Pharmacology 14, 1163391. https:\/\/doi.org\/10.3389\/fphar.2023.1163391","DOI":"10.3389\/fphar.2023.1163391"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Zampoli, M., Verstraete, J., Baird, C., Biebuyck, T., Calligaro, G., Coetzee, M. et al., 2025b, \u2018Real-world outcomes of generic elexacaftor\/tezacaftor\/ivacaftor (gETI) in South Africans with CF using standard versus clarithromycin-boosted gETI\u2019, Journal of Cystic Fibrosis 24(2), 284\u2013289. https:\/\/doi.org\/10.1016\/j.jcf.2025.02.002","DOI":"10.1016\/j.jcf.2025.02.002"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Zampoli, M., Verstraete, J., Baird, C., Calligaro, G. & Morrow, B., 2023b, \u2018Affordable cystic fibrosis (CF) transmembrane conductance regulator modulator drugs for CF: All CF lives worldwide matter!\u2019, American Journal of Respiratory and Critical Care Medicine 208(9), 915\u2013916. https:\/\/doi.org\/10.1164\/rccm.202307-1200VP","DOI":"10.1164\/rccm.202307-1200VP"},{"key":"ref43","unstructured":"Zampoli, M., Verstraete, J., Frauendorf, M. & The CF Steering Committee, 2023c, South African cystic fibrosis patient registry report 2023, South African Cystic Fibrosis Association, Cape Town, viewed 19 May 2026, from https:\/\/sacfa.org.za\/registry-report-2023\/."}],"container-title":["South African Journal of Physiotherapy"],"original-title":[],"link":[{"URL":"https:\/\/sajp.co.za\/index.php\/sajp\/article\/view\/2422\/4300","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T07:33:50Z","timestamp":1786692830000},"score":1,"resource":{"primary":{"URL":"https:\/\/sajp.co.za\/index.php\/sajp\/article\/view\/2422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.4102\/sajp.v82i1.2422","relation":{},"ISSN":["0379-6175","2410-8219"],"issn-type":[{"value":"0379-6175","type":"print"},{"value":"2410-8219","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"a2422"}}